enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. How a new FDA-approved drug can — and can’t — help people ...

   www.aol.com/fda-approved-drug-t-help-121600044.html

   How a new FDA-approved drug can — and can’t — help people with Alzheimer’s November 21, 2024 at 12:28 PM If you have a loved one with Alzheimer’s disease, you may have read about a newly ...

3. FDA To Review New Alzheimer's Drug Leqembi and How ... - AOL

   www.aol.com/fda-review-alzheimers-drug-leqembi...

   An Alzheimer’s disease drug may soon have a new dosing schedule. The medication, Leqembi, is currently administered via an infusion every two weeks. Under the proposed changes, the medication ...

4. Donanemab – what we know about the latest Alzheimer’s drug

   www.aol.com/donanemab-know-latest-alzheimer-drug...

   The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in research because they target a known cause of the disease, rather than just treating ...

5. Alzheimer's: Are newly approved drugs making a real-life ...

   www.aol.com/alzheimers-newly-approved-drugs...

   Safety risks and accessibility of new Alzheimer’s drugs. The modest clinical benefits conferred by anti-amyloid antibody treatments need to be weighed against the risks, costs, and accessibility ...

6. Aducanumab - Wikipedia

   en.wikipedia.org/wiki/Aducanumab

   Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. [2] [3] It is a monoclonal antibody [3] [2] that targets aggregated forms (plaque) [4] [5] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup.

7. Everything we know about breakthrough Alzheimer’s drug Donanemab

   www.aol.com/everything-know-breakthrough...

   A new Alzheimer's drug is being hailed as a "turning point" in the fight against the disease, with researchers saying it marks the beginning of a "new era where Alzheimer's could become treatable".

8. Crenezumab - Wikipedia

   en.wikipedia.org/wiki/Crenezumab

   Crenezumab was developed by Ruth Greferath, Ph.D., and Claude Nicolau, Ph.D., before the Swiss-based biopharmaceutical company AC Immune was founded, which focuses on developing targeted therapeutics for misfolded proteins that cause neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. [4]

9. Major US health systems expect to offer Alzheimer's drug ...

   www.aol.com/news/major-us-health-systems-expect...

   Leqembi, which won full U.S. regulatory approval last month, is the first treatment proven to slow progression of the mind-robbing disease for people in the earliest stages of Alzheimer's.